Earnings Snapshot: Medtronic Beats, Krystal Shines, Genuine Parts Misses

The recent earnings reports from Medtronic (MDT), Genuine Parts Company (GPC), and Krystal Biotech (KRYS) offer a glimpse into the diverse sectors these companies operate within, showcasing a mix of triumphs and challenges. Medtronic, a titan in healthcare technology, reported robust growth, surpassing both EPS and revenue expectations. On the other hand, Genuine Parts Company faced some hurdles, with their earnings falling short of expectations. Meanwhile, Krystal Biotech exceeded its financial targets, driven by the strong performance of its flagship product, VYJUVEK.

How Each Company Performed This Quarter

Medtronic’s third quarter of fiscal 2026 was marked by strong financial performance, with the company reporting an EPS of $1.36 against an expectation of $1.34, and revenue of $9 billion, slightly above the anticipated $8.91 billion.

This performance was largely driven by an impressive 80% growth in the Cardiac Ablation Solutions segment, which benefited from the strength of the pulsed field ablation portfolio. The company’s cardiovascular portfolio saw an 11% year-over-year increase, contributing significantly to the highest enterprise revenue growth Medtronic has seen in a decade.

Genuine Parts Company, however, reported a challenging fourth quarter of 2025. The company recorded an EPS of $1.55, falling short of the expected $1.81, and revenue of $6 billion, slightly below the $6.06 billion forecast.

The company attributed its performance to non-recurring charges and strategic restructuring initiatives. Despite the shortfall, Genuine Parts Company announced a dividend increase for the 70th consecutive year, reflecting its commitment to returning value to shareholders.

Krystal Biotech, on the other hand, reported a successful fourth quarter, with an EPS of $1.70, surpassing the expected $1.58, and revenue of $107.1 million, above the anticipated $106.16 million. The company’s flagship product, VYJUVEK, generated significant revenue, contributing to the overall positive financial performance. The company also highlighted its progress in expanding its pipeline and securing regulatory designations for its products.

Join our Telegram group and never miss a breaking digital asset story.

Full-Year Outlook and Key Initiatives

Looking ahead, Medtronic remains optimistic about its fiscal 2026 guidance, reiterating its organic revenue growth target of approximately 5.5% and a non-GAAP EPS range of $5.62 to $5.66. The company plans to continue investing in high-growth opportunities and its innovation pipeline, which it believes will sustain long-term growth.

Medtronic also highlighted its ongoing M&A strategy, which includes key transactions in the Coronary and Renal Denervation and Structural Heart segments.

Genuine Parts Company’s outlook for 2026 includes a total sales growth target of 3% to 5.5%, with expectations of 3% to 6% growth across its North America Automotive, International Automotive, and Industrial segments.

The company plans to separate its automotive and industrial businesses into two independent public companies, a move expected to unlock additional value and position the businesses for future growth. Genuine Parts Company also highlighted its strong liquidity position, with $1.5 billion in total liquidity at the end of 2025.

Krystal Biotech provided guidance for its fiscal 2026, with a focus on expanding its global reach and advancing its pipeline. The company aims to achieve non-GAAP R&D and SG&A expenses between $175 million and $195 million.

Krystal Biotech is also on track to expand its specialty distributor network to over 40 countries by the end of 2026. The company plans to continue its clinical development efforts across its pipeline, with several key study readouts anticipated in the coming year.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.